Key Highlights

  • Shares fell 11.34% to USD 5.24 in pre-market trading on November 4, 2026, from a USD 5.91 close on November 3.
  • Second quarter 2026 Revenue was USD 1.97 million, up about 14% from roughly USD 1.7 million a year earlier.
  • Gross Margin reached 76% in the second quarter, compared with 56% in the prior-year period.
  • Net loss narrowed to about USD 4.8 million from about USD 12.6 million.
  • The company reported cash of about USD 3.9 million at June 30, 2026, plus later financing proceeds.

What Moved Nuwellis Before the Open (down USD 0.6702, 11.34%)

Nuwellis (NASDAQ:NUWE) was down 11.34% at USD 5.24 in pre-market trading on November 4, 2026, a decline of USD 0.6702 from the Tuesday November 3, 2026 close of USD 5.91.

No company announcement dated November 3 or November 4, 2026 was identified in the research, so the decline is not tied to a confirmed catalyst. A plausible backdrop is profit-taking after a sharp run that followed the reverse stock split.

Recent Company Updates Behind the Volatility

The company disclosed a Reverse Stock Split in a regulatory filing dated October 23, 2026, with split-adjusted trading scheduled to begin on October 27, 2026. The split ratio was not available in the sources reviewed. On October 27, 2026 the company also announced acceptance of a multicenter pediatric Aquadex study in a pediatric nephrology journal.

Earlier, on October 8, 2026, the company said it would convene a pediatric medical and nursing advisory board on November 18 and 19, 2026. About 12 clinicians from 11 U.S. pediatric centers are expected to evaluate its Vivian pediatric continuous renal replacement therapy system, which is still in development.

Business Background and Latest Results

Nuwellis is a medical technology company whose Aquadex SmartFlow system provides ultrafiltration, a therapy that removes excess fluid from patients with fluid overload, including heart failure.

On September 17, 2026 the company said it had sold 31 Aquadex consoles year to date in 2026, more than its full-year console sales in seven of the previous ten years. It also reported 26% year-over-year U.S. revenue growth in the first half of 2026.

For the quarter ended June 30, 2026, reported on August 13, 2026, revenue was USD 1.97 million, up about 14%, with U.S. revenue up 17%. Operating expenses were about USD 4.7 million. The net loss of about USD 4.8 million included roughly USD 1.7 million of Warrant valuation expense.

Balance Sheet, Financing and Risks

Cash was about USD 3.9 million at June 30, 2026, with no debt. After the quarter ended, the company raised about USD 3.4 million in a registered direct offering and about USD 3.3 million from warrant exercises. The company has said this supports its cash runway into the second quarter of 2027.

The quarterly filing also carried going-concern and Nasdaq listing compliance risk language. Annual operating cash outflow for 2025 was about USD 10.8 million, so continued Capital raising and dilution remain real possibilities for a company of this size.

The shares are volatile and thinly traded.

What to Watch Next

The next scheduled event is the third quarter 2026 report, expected in November 2026; the company has not confirmed the date in the sources reviewed. Revenue growth, gross margin, console placements and updated cash figures will show whether the second quarter trends held.

The pediatric advisory board meeting on November 18 and 19, 2026 is the next milestone for Vivian.